πŸ‡ΊπŸ‡Έ FDA
Patent

US 12274696

Methods of administering nalbuphine

granted A61KA61K31/485A61K9/205

Quick answer

US patent 12274696 (Methods of administering nalbuphine) held by Trevi Therapeutics, Inc. expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Trevi Therapeutics, Inc.
Grant date
Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/485, A61K9/205, A61P, A61P11/00